- Esperion Therapeutics ( NASDAQ: ESPR ) is scheduled to announce Q4 earnings results on Tuesday, February 21st, before market open.
- The consensus EPS Estimate is -$0.85 (vs. -$1.77 last year) and the consensus Revenue Estimate is $20.6M (+33.8% Y/Y).
- Over the last 1 year, ESPR has beaten EPS estimates 75% of the time and has beaten revenue estimates 25% of the time.
- Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 1 upward revision and 2 downward.
For further details see:
Esperion Therapeutics Q4 2022 Earnings Preview